M&As this week: Strides Pharma Science, Lambda Therapeutic Research, NextPharma

1 February 2019 (Last Updated February 4th, 2019 16:27)

Strides Pharma Science’s step-down subsidiary Strides Pharma has made an arrangement to acquire Vensun Pharmaceuticals for $18m.

Strides Pharma Science’s step-down subsidiary Strides Pharma has made an arrangement to acquire Vensun Pharmaceuticals for $18m.

Strides has agreed to make an upfront payment of $4m upon closing of the transaction and repay a $14m debt owed by the target company. A deferred consideration up to $75m will also be paid over a period of six years.

The acquirer will gain access to additional 16 approved ANDAs and 12 files pending approval.

Strides Pharma is an Indian pharmaceutical company focused on developing anti-viral and antibiotic products, while Vensun Pharmaceuticals is a generic pharmaceutical company based in the US.

“The latest acquisition is Lambda’s second transaction in North America, the first being that of Biovail’s contract research division in 2010.”

Kegler Brown Hill & Ritter and Goodwin Procter are the respective legal advisers to Stridesand Vensun for the transaction, while SVB Leerink is the financial adviser to Vensun.

Lambda Therapeutic Research has entered an agreement to acquire Novum Pharmaceutical Research Services in a private transaction, whose terms have not been disclosed.

The acquisition will allow Lambda to strengthen its global presence and capabilities in the US market.

Lambda Therapeutic Research is a leading contract research organisation (CRO) in India, while Novum Pharmaceutical Research is a US-based CRO engaged in providing clinical research and data management services to the pharmaceutical industry.

Novum will become a wholly owned subsidiary of Lambda, following the transaction.

The latest acquisition is Lambda’s second transaction in North America, the first being that of Biovail’s contract research division in 2010.

NextPharma has signed an agreement to acquire Santen’s manufacturing facility and associated operations in Tampere, Finland, by mid-2019.

The acquisition will add ophthalmology manufacturing and sterile blow fill seal (BFS) technology to NextPharma.

Based in the UK, NextPharma is a pharmaceutical contract development and manufacturing organisation (CDMO), while Santen is a Japanese developer of ophthalmic pharmaceutical products.